CA2865774A1 - Psma as a biomarker for androgen activity in prostate cancer - Google Patents

Psma as a biomarker for androgen activity in prostate cancer Download PDF

Info

Publication number
CA2865774A1
CA2865774A1 CA2865774A CA2865774A CA2865774A1 CA 2865774 A1 CA2865774 A1 CA 2865774A1 CA 2865774 A CA2865774 A CA 2865774A CA 2865774 A CA2865774 A CA 2865774A CA 2865774 A1 CA2865774 A1 CA 2865774A1
Authority
CA
Canada
Prior art keywords
psma
imaging
patient
prostate cancer
measurement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2865774A
Other languages
English (en)
French (fr)
Inventor
Neil H. Bander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CA2865774A1 publication Critical patent/CA2865774A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2865774A 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer Abandoned CA2865774A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604039P 2012-02-28 2012-02-28
US61/604,039 2012-02-28
PCT/US2013/000051 WO2013130177A1 (en) 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer

Publications (1)

Publication Number Publication Date
CA2865774A1 true CA2865774A1 (en) 2013-09-06

Family

ID=49083148

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865774A Abandoned CA2865774A1 (en) 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer

Country Status (6)

Country Link
US (1) US20130315830A1 (https=)
EP (1) EP2819704A4 (https=)
JP (1) JP2015508903A (https=)
CA (1) CA2865774A1 (https=)
HK (1) HK1202256A1 (https=)
WO (1) WO2013130177A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904969C (en) 2013-03-13 2025-06-17 Imaginab, Inc. DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
KR20210087938A (ko) * 2018-09-28 2021-07-13 이미지냅 인코포레이티드 Cd8 이미징 구조체 및 이의 사용 방법
US20240011996A1 (en) * 2020-11-24 2024-01-11 Korea Institute Of Science And Technology Biomarkers for diagnosing prostate cancer, combination thereof, and use thereof
EP4267969A4 (en) * 2020-12-22 2025-02-12 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF PROSTATE CANCER

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098885A1 (en) * 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
WO2007109347A2 (en) * 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and ly6 e: targets for cancer diagnosis and therapy
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
US20100047166A1 (en) * 2008-08-20 2010-02-25 Kanner Steven B Antibodies and related molecules that bind to 58p1d12 proteins
EP2398504B1 (en) * 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP3222617B1 (en) * 2009-03-19 2022-07-06 The Johns Hopkins University Psma-targeting compounds and uses thereof
EP2419507A1 (en) * 2009-04-14 2012-02-22 Institut Gustave Roussy Prostate cancer cell lines and their use in screening method
WO2013126147A2 (en) * 2012-02-24 2013-08-29 Cornell University Elevated psma identifies lethal prostate cancers

Also Published As

Publication number Publication date
EP2819704A1 (en) 2015-01-07
EP2819704A4 (en) 2015-10-21
HK1202256A1 (en) 2015-09-25
JP2015508903A (ja) 2015-03-23
WO2013130177A1 (en) 2013-09-06
US20130315830A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
Chen et al. TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency
Tiwari et al. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer
US20130315830A1 (en) PSMA as a BioMarker for Androgen Activity in Prostate Cancer
Surowiak et al. ABCC2 (MRP2, cMOAT) can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome
Blouw et al. The invadopodia scaffold protein Tks5 is required for the growth of human breast cancer cells in vitro and in vivo
US20250230259A1 (en) Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability
Nickkho-Amiry et al. Peroxisome proliferator–activated receptors modulate proliferation and angiogenesis in human endometrial carcinoma
Makris et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study
Chen et al. Serum exosomal miR‐16‐5p functions as a tumor inhibitor and a new biomarker for PD‐L1 inhibitor‐dependent immunotherapy in lung adenocarcinoma by regulating PD‐L1 expression
Long et al. Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression
Wang-Rodriguez et al. Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status
Longo et al. ErbB4 promotes malignant peripheral nerve sheath tumor pathogenesis via Ras-independent mechanisms
AU2016270686A1 (en) Quantifying Her2 protein for optimal cancer therapy
Ke et al. Mechanical signal modulates prostate cancer immune escape by USP8-mediated ubiquitination-dependent degradation of PD-L1 and MHC-1
Wang et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts
Feng et al. Deubiquitinase USP10 promotes osteosarcoma autophagy and progression through regulating GSK3β-ULK1 axis
Liu et al. Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression
Ames et al. Huntingtin-interacting protein 1: a Merkel cell carcinoma marker that interacts with c-Kit
Gaber et al. Obesity increases DNA damage in the breast epithelium
Chocarro-Calvo et al. Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progression
Lang et al. A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy
Diao et al. MEK5 overexpression is associated with the occurrence and development of colorectal cancer
US7718393B2 (en) Method for determining the efficacy of an anthracycline anticancer agent
Huang et al. Clinicopathological and cellular signature of PAK1 in human bladder cancer
Halin Bergström et al. High‐grade tumours promote growth of other less‐malignant tumours in the same prostate

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180226

FZDE Discontinued

Effective date: 20210831